Amediplase. Menarini.
Amediplase, a chimeric protein containing functional domains of both tissue plasminogen activator and pro-urokinase plasminogen activator, is under development by Menarini for the potential treatment of thrombosis. Phase III trials with amediplase were underway by June 2002.
Doggrell
Sheila A
SA
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s_doggrell@yahoo.com
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D005343:Fibrinolytic Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins; D013329:Structure-Activity Relationship; D013927:Thrombosis / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C473928:amediplase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator